Infant milk formulas differ regarding their allergenic activity and induction of T-cell and cytokine responses

H. Hochwallner, U. Schulmeister, I. Swoboda, M. Focke-Tejkl, R. Reininger, V. Civaj, R. Campana, J. Thalhammer, S. Scheiblhofer, N. Balic, F. Horak, M. Ollert, N. G. Papadopoulos, S. Quirce, Z. Szepfalusi, U. Herz, E. A. F. van Tol, S. Spitzauer & R. Valenta

1 Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna; 2 Department of Medical & Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna; 3 Department of Molecular Biology, Christian Doppler Laboratory for Allergy Diagnosis & Therapy, University of Salzburg, Salzburg; 4 Allergy Centre Vienna West, Vienna, Austria; 5 Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg; 6 Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense, Denmark; 7 Allergy Research Center, 2nd Pediatric Clinic, University of Athens, Athens, Greece; 8 Center for Pediatrics and Child Health, Institute of Human Development, University of Manchester, Manchester, UK; 9 Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; 10 Department of Pediatrics, Medical University of Vienna, Vienna, Austria; 11 Mead Johnson Nutrition, Evansville, IN, USA.

Keywords
cow’s milk allergy; hydrolyzed milk formulas; pro-inflammatory cytokines; T-cell reactivity.

Abstract
Background: Several hydrolyzed cow’s milk (CM) formulas are available for avoidance of allergic reactions in CM-allergic children and for prevention of allergy development in high-risk infants. Our aim was to compare CM formulas regarding the presence of immunoreactive CM components, IgE reactivity, allergenic activity, ability to induce T-cell proliferation, and cytokine secretion.

Methods: A blinded analysis of eight CM formulas, one nonhydrolyzed, two partially hydrolyzed (PH), four extensively hydrolyzed (EH), and one amino acid formula, using biochemical techniques and specific antibody probes was conducted. IgE reactivity and allergenic activity of the formulas were tested with sera from CM-allergic patients (n = 26) in RAST-based assays and with rat basophils transfected with the human FcεRI, respectively. The induction of T-cell proliferation and the secretion of cytokines in Peripheral blood mononuclear cell (PBMC) culture from CM allergic patients and nonallergic individuals were assessed.

Results: Immune-reactive α-lactalbumin and β-lactoglobulin were found in the two PH formulas and casein components in one of the EH formulas. One PH formula and the EH formula containing casein components showed remaining IgE reactivity, whereas the other hydrolyzed formulas lacked IgE reactivity. Only two EH formulas and the amino acid formula did not induce T-cell proliferation and proinflammatory cytokine release. The remaining formulas varied regarding the induction of Th2, Th1, and proinflammatory cytokines.

Conclusion: Our results show that certain CM formulas without allergenic and low proinflammatory properties can be identified and they may also explain different outcomes obtained in clinical studies using CM formulas.

Abbreviations
CM, cow’s milk; IgE, immunoglobulin E; RBL, rat basophil leukemia; rlf, recombinant lactoferrin; α-la, recombinant alpha-lactalbumin; rαS1-cas, recombinant alphaS1-casein; rαS2-cas, recombinant alphaS2-casein; rβ-cas, recombinant beta-casein; rβ-lg, recombinant beta-lactoglobulin; rκ-cas, recombinant kappa-casein.
Food allergy is increasing and represents an important public health problem (1, 2). Cow’s milk (CM) is one of the most important allergen sources particularly in children and can elicit severe life-threatening reactions in sensitized patients (3, 4). The molecular nature of CM allergens and the allergic immune responses in terms of antibody and cellular responses are subject of several studies with the goal to develop diagnostic, therapeutic, and preventive strategies for CM allergy (5).

For children who cannot be breastfed, the use of hydrolyzed CM formulas has been recommended for the prevention of allergic reactions to CM in allergic children (i.e. for treatment) as well as for the prevention of allergic sensitization and allergy development in high-risk children (6–9).

Cow’s milk formulas differ regarding the degree of hydrolysis of the milk proteins as well as regarding the hydrolysis procedure ranging from partially to extensively hydrolyzed (EH) formulas. Amino acid substitutes are available for highly CM-allergic infants. Furthermore, CM formulas are named depending on their protein source, such as whey or casein hydrolyzates (10). Partially hydrolyzed (PH) formulas are supposed to contain small and larger oligopeptides with a molecular weight of <5 kDa, EH formulas should contain only peptides with a molecular weight of <3 kDa, and amino acid-based formulas (AA) are made of essential and nonessential amino acids (10).

In a series of early intervention studies using hydrolyzed CM formulas, it could be shown that certain formulas were useful for allergy prevention in the first year of life (11) and reduced the incidence of atopic dermatitis (AD) at the age of 3 and 6 years and this preventive effect persisted until the age of 10 years without rebound (12–14).

Here, we conducted a blinded analysis of eight CM formulas: one nonhydrolyzed, two PH, four EH, and one amino acid formula, regarding their biochemical composition, the presence of antibody-reactive CM allergens/allergen fragments, IgE reactivity, abilities to induce basophil activation, T-cell proliferation, and secretion of a panel of different cytokines. Our study revealed major differences among the formulas regarding the presence of immunogenic allergens/allergen fragments, IgE reactivity, allergic activity, induction of T-cell responses, and cytokine secretion. In particular, we were able to demonstrate a strongly varying capacity of the formulas to induce the secretion of Th1, Th2, and other proinflammatory cytokines. Our results may provide not only an explanation for the selective effects of CM formulas on the prevention of allergic sensitization and certain allergic manifestations. They also indicate that CM formulas with low proinflammatory activity can be identified, which may have potential for prevention of other inflammatory diseases.

### Materials and methods

#### Biological materials

In total, 10 coded CM formulas were analyzed in a blinded manner regarding their biochemical and immunological characteristics. Only after completion of the analysis, their identity was disclosed. Table 1 provides a summary and characterization of the 10 CM formulas regarding their manufacturer, source, degree of hydrolysis, protein, and endotoxin contents.

The endotoxin levels of the formulas were measured with Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Scientific, Vienna, Austria) as described in the user manual.

Antibody probes specific for the individual CM proteins were produced as follows: cDNA coding for several CM

---

| Milk samples | Product        | Manufacturer | Condition     | Protein content (g/100 g) | Endotoxin content (EU in 100 μg protein) |
|--------------|----------------|--------------|---------------|--------------------------|-------------------------------------------|
| M1           | Enfamil premium | Mjn          | C+W           | 11.00                    | 0.035                                     |
| M2           | Enfamil HA-Gentlease | Mjn         | C+W           | 12.80                    | 0.035                                     |
| M3           | Nutramigen      | Mjn          | C             | 14.00                    | 0.036                                     |
| M4           | Nutramigen AA   | Mjn          | AA            | 14.00                    | 0.041                                     |
| M5           | Nan HA          | Nestle       | W             | 11.50                    | 0.034                                     |
| M6           | Friso allergycare | Friso       | C             | 11.70                    | 0.036                                     |
| M7           | Alimentum advance | Ross       | C             | 13.93                    | 0.030                                     |
| M8           | Alfare          | Nestle       | W             | 14.80                    | 0.039                                     |
| M9           | Milk protein    | Mjn          | C+W           | 36.00                    | 0.046                                     |
| M10          | Whey            | Mjn          | W             | 36.10                    | 0.048                                     |

HA, hypoallergenic; Mjn, Mead Johnson Nutrition; C, casein; W, whey; AA, amino acids; EH, extensively hydrolyzed; PH, partially hydrolyzed.
allergens were isolated by IgE immunoscreening of a cDNA expression library prepared from bovine mammary glands (15). Recombinant CM allergens (alphaS1-casein, alphaS2-casein, beta-casein, kappa-casein, alpha-lactalbumin, beta-lactoglobulin, lactoferrin) were expressed in *Escherichia coli* strain BL21 Codon Plus (DE3)-RIPL (Stratagene, La Jolla, CA, USA) as hexahistidine-tagged proteins and purified by Ni\(^{2+}\) affinity chromatography (QIAGEN, Hilden, Germany) as described by Schulmeister et al. (15).

Allergen-specific rabbit antibodies were obtained by immunizing rabbits three times (once in CFA and twice in incomplete Freund’s adjuvant (IFA)) with the purified recombinant proteins (Charles River, Kisslegg, Germany).

**Serum and blood samples**

Serum and blood samples were obtained from CM-allergic patients (*n* = 26), patients who suffered from symptoms after CM consumption but without CM-specific IgE (*n* = 2), subjects with CM-specific IgE but without symptoms (*n* = 4), and from six nonallergic subjects. The diagnosis of CM allergy was based on the presence of clinical symptoms that could be unambiguously attributed to consumption of CM and/or on results of an open food challenge, a positive skin prick test reaction, and the presence of specific IgE to CM allergens as measured by ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden) (Table 2). Hypolactasia was not investigated in the CM-allergic patients because it does not affect immune reactivity to CM components. In addition to the CM-allergic subjects, we tested also serum and blood samples from nonallergic subjects, two patients with symptoms upon CM contact (cough, gastrointestinal problems) lacking CM-specific IgE, and four subjects with CM-specific IgE without symptoms to CM (Table 2). Serum and blood samples were analyzed in an anonymized manner with permission of the Ethics Committee of the Medical University of Vienna (EK565/2007; EK1641/2014). For freshly taken blood samples, informed written consent was obtained from the subjects. Clinical and demographic features of the subjects are summarized in Table 2.

**Analysis of formulas by SDS-PAGE and by dot blotting with specific antibody probes**

Protein, peptide, and amino acid contents in the milk formulas were determined by measuring protein nitrogen in the samples by the Kjeldahl method (16). Aliquots of 30 μg/lane of the milk samples were subjected to SDS-PAGE and Coomassie Brilliant Blue staining (17). For immunoblot analysis, 1 μg aliquots of the milk samples were dotted onto a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). Dot blotting instead of Western blotting was chosen in order not to lose small peptides during gel electrophoresis and electroblotting and to avoid denaturing conditions that may affect IgE reactivity. The nitrocellulose strips were blocked with PBST (PBS, 0.5% v/v Tween 20) and exposed to rabbit antiserum (1 : 2000 diluted) or to sera from CM-allergic patients and nonallergic individuals (1 : 10 or 1 : 20 diluted) overnight at 4°C. Bound rabbit IgG antibodies were detected with 125I-labeled donkey anti-rabbit IgG (Perkin Elmer, Boston, MA, USA) diluted 1 : 2000 in PBST or in the case of human IgE antibodies with 125I-labeled anti-human IgE antibodies (IBL, Hamburg, Germany), diluted 1 : 15. Positive signals were visualized by autoradiography using Kodak XOMAT films with intensifying screens (Kodak, Vienna, Austria) at −80°C.

**Rat basophil leukemia assays**

For the assessment of the allergenic activity of the milk samples, huRBL cell mediator release assays were performed as

---

### Table 2 Demographic and clinical features of patients and control individuals

| Patient | Sex M/F | Age | Milk-related symptoms | Other allergies | Total IgE (kU/l) | Spec. IgE to CM (kUA/l) |
|---------|---------|-----|----------------------|----------------|----------------|-------------------------|
| A: Nonallergic individuals (*n* = 6) | 2/4 | 21–51 years | No | No | 5.8–91.1 | <0.35 |
| B: CM allergic patients (*n* = 26) | 14/9 | 4 months to 70 years | AD, AE, AS diarrea, E, eczema Gl, Rh, U, V, Sys | Animal dander, candida, cat, dog fish, hazelnut, HE, mite, moulds nuts, PO, soy, wheat | 3.58–3350 | 1.3–>100 |
| C: Patients without CM-specific IgE but with symptoms (*n* = 2) | 1/1 | 25–53 years | CO, Gl | Cat, mite | 64.9–153 | <0.35 |
| D: Patients with CM-specific IgE but without symptoms (*n* = 4) | 2/2 | 5–55 years | No | Birch, HE, PO, sheep milk | 14.1–1844 | 0.79–7 |

F, female; M, male; Symptoms: AD, atopic dermatitis; AE, angioedema; AS, asthma; E, edema; Gl, gastrointestinal symptoms; Rh, rhinitis; U, urticaria; V, vomiting; Sys, systemic reactions; CO, cough; Allergen (source): HE, hen’s egg; PO, pollen; kU/l, total IgE in kilo units/liter; kUA/l, allergen-specific IgE in kilo units antigen/liter; CM, cow’s milk; nk, not known.
described previously (15, 18). In brief, rat basophil leukemia (RBL) cells (clone RBL-703/21) transfected with the human FcεRI were incubated with sera from CM-allergic patients overnight. On the next day, the cells were washed, and 100 μl of milk components (concentration: 0.3 μg/ml total protein contents) were added and incubated for 1 h at 37°C, 7% CO₂, 95% humidity. Aliquots of the supernatants were mixed with assay solution (0.1 M citric acid or sodium citrate, pH 4.5 and 160 μM 4-methyl umbelliferyl-N-acetyl-β-D-glucosamidase) and incubated for 1 h at 37°C, 7% CO₂, 95% humidity. Fluorescence was measured with a fluorescence microplate reader, and specific release could be calculated. Values obtained with buffer alone were subtracted, and the values exceeding 10% of total release were considered as positive.

**Lymphocyte proliferation assays**

PBMCs from six nonallergic individuals and seven CM-allergic patients were isolated from heparinized blood samples by Ficoll density gradient centrifugation (Amersham Biosciences, Uppsala, Sweden). PBMCs (2 × 10⁵ cells/well) were cultured in triplicates in 96-well plates (Nunclone; Nalgen Nunc International, Roskilde, Denmark) in 200 μl serum-free Ultra Culture medium (BioWhittaker, Rockland, ME, USA) supplemented with 2 mM L-glutamine (Gibco, Carlsbad, CA, USA), 50 μM β-mercaptoethanol (Gibco), and 0.1 mg gentamicin per 500 ml (Gibco). The cells were incubated at 37°C in a humified atmosphere with 5% CO₂ for 7 days and stimulated with different concentrations of milk samples (0.05, 0.5, 3, and 10 μg/ml), 4 U IL-2 per well (Roche) as a positive control and medium alone as a negative control in duplicate. After 6 days of incubation, 0.5 mCi ³H-thymidine (Amersham, Buckinghamshire, UK) was added to each well for 16 h, and then, the incorporated radioactivity was measured by liquid scintillation counting. Proliferation was expressed as counts per minute (c.p.m.; means of triplicates) using a microbeta scintillation counter (Wallac ADL, Freiburg, Germany). The mean stimulation indices (SI) were calculated as quotient of triplicate c.p.m. with antigen vs medium and shown are the SI obtained by stimulation with 10 μg protein/well.

**Analysis of cytokine levels in supernatants**

Cytokine levels (IL-5, IL-6, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF) were measured in supernatants collected from PBMC cultures at day 6 of culture using xMAP Luminex fluorescent bead-based technology. The assays were performed according to the manufacturer’s instructions (R&D Systems, Wiesbaden, Germany), and fluorescent signals were read on a Luminex 100 system (Luminex Corp., Austin, TX, USA). The limits of detection were 1.9 pg/ml for IL-5, 5.5 pg/ml for IL-6, 3.1 pg/ml for IL-10, 47 pg/ml for IL-13, 2.9 pg/ml for IFN-γ, 5.3 pg/ml for TNF-α, and 3.3 pg/ml for GM-CSF. Shown are means of triplicate determinations from cultures stimulated with 10 μg protein/well.

**Statistics**

Statistical comparisons were performed by Mann–Whitney U-test for nonparametric values. P-values < 0.05 were considered as significant. For all calculations, the statistical program PASW Statistics 18 (Version 18.0.0. 1993–2007; Polar Engineering and Consulting Nikiski, Alaska, United States) was used.

**Results**

**Biochemical and immunochemical analysis indicates different compositions of milk formulas**

In the first step, formulas M1 to M10 were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue to visualize intact proteins. This analysis demonstrated the presence of several proteins with molecular masses between 10 and 100 kDa in the formulas M1, M9, and M10 and to lesser extent in M3 (Fig. 1A). Protein smear below 20 kDa was found in M2 and M5, whereas in M4, M6, M7, and M8, no protein staining was observed (Fig. 1A). The measurement of the endotoxin levels in the 10 samples showed low levels of endotoxin (<0.05 EU in 100 μg protein) (Table 1).

In the next step, we used specific antibodies raised against purified recombinant CM allergens (rαS1-cas, rαS2-cas, β-cas, rk-cas, rα-la, rβ-lg, rlf) to detect immunoreactive components in the formulas in dot blot experiments (Fig. 1B). The whole CM protein-containing formula M1 and the milk protein control M9 reacted with each of the antisera demonstrating the presence of the proteins of the casein fraction (αS1-cas, αS2-cas, β-cas, k-cas) and from the whey fraction (α-la, β-lg, llf). In M2, a PH formula that is made up from casein and whey, mainly α-la and β-lg and to a much lower degree, αS2-cas was detected. The other PH formula M5 also contained immunoreactive α-la and β-lg. Interestingly, the EH formula M8 that is produced of the whey fraction contains mainly the immunoreactive caseins but whey protein could not be detected. In the whey fraction M10, each of the whey proteins (i.e. α-la, β-lg, and lactoferrin) was detected. No immunoreactive proteins of the casein and whey fraction were detected in the formulas M3, M4, M6, and M7.

**Milk formulas show major differences regarding IgE reactivity and allergenic activity**

In the next step, the IgE reactivities of the samples were tested with a highly sensitive RAST-based dot blot analysis using sera from 21 CM-allergic patients, two patients with symptoms after CM consumption lacking milk-specific IgE, a nonallergic control, and four patients with CM-specific IgE antibodies but without symptoms (Fig. 2). Almost each of the 21 CM-allergic patients showed IgE reactivity to M1, M9, and M10. There were differences regarding IgE reactivity to M1, M9, and M10, which may be attributed to a different sensitization of the patients to caseins and whey proteins. IgE reactivity to M8 was found for patients 7, 8, 12, 13, 16, 18, 19, 21, and 22 (Fig. 2). Patients 1, 5, 7, 8, 19,
20, 21, and 22 reacted with M2. Patient 19 and 17 showed weak IgE reactivity to M5 and M7, respectively (Fig. 2). Patients 8 and 17 showed reactivity to M7. None of the other formulas M3, M4, and M6 showed relevant IgE reactivity. The control serum from the nonallergic person 25 showed no IgE reactivity to any of the dotted formulas (Fig. 2).

The assessment of the allergenic activity of the milk formulas by basophil degranulation experiments was in quite good agreement with the IgE reactivity data. We found that mainly the samples M1, M9, and M10 induced mediator release in CM-allergic patients. Furthermore, M8 induced degranulation in cells loaded with sera from patients 19 and 22 (data not shown).

**Different capacity of milk formulas to induce lymphocyte proliferation**

Next, we tested the ability of the milk formulas to induce lymphocyte proliferation in cultured PBMCs from seven CM-allergic and six nonallergic individuals (Fig. 3). Except for the whole milk preparation M9, nonhydrolyzed (M1, M10) and PH formulas (M2, M5) showed the highest median SI (M1: nonallergic: SI 5.3, CM allergic: SI 4.3; M2: nonallergic: SI 4.5, CM allergic: SI 2.6; M5: nonallergic: SI 3.9, CM allergic: SI 2.7, M9: nonallergic: SI 2.1, CM allergic: SI 1.8) (Fig. 3). Among the EH formulas, the median SI were higher for M6 (nonallergic: SI 3.3, CM allergic: SI 1.6) and...
Milk formulas differ in allergenic activity

Hochwallner et al.

Identification of milk formulas that induce low levels of proinflammatory cytokines

The PBMC culture supernatants from nonallergic individuals and CM-allergic patients stimulated with the milk formulas M1–M10 were analyzed regarding the secretion of various cytokines by Luminex analysis (Fig. 4). The EH formulas M3 and M6 and the amino acid formulation M4 were the milk formulas that induced low levels of all tested cytokines. Similarly, the EH formula M8 induces low levels for most cytokines by Luminex analysis (Fig. 4). The EH formulas M1 and CM-allergic patients stimulated with the milk formulas M1–M10 (x-axis). Box plots of stimulation indices with indicated medians for nonallergic (white) and allergic subjects (gray) are displayed (y-axis). Asterisks are extreme outliers, and circles represent mild outliers. *Statistical significant difference (P < 0.05).

Figure 3 Lymphoproliferative responses in PBMCs induced by milk formulas M1–M10. PBMCs from six nonallergic individuals and from seven cow’s milk (CM)-allergic patients were stimulated with milk formulas (M1–M10) (x-axis). Box plots of stimulation indices with indicated medians for nonallergic (white) and allergic subjects (gray) are displayed (y-axis). Asterisks are extreme outliers, and circles represent mild outliers. *Statistical significant difference (P < 0.05).

M7 (nonallergic: SI 2.9, CM allergic: SI 1.8), whereas M3 (nonallergic: SI 1.4, CM allergic: SI 1.3) and M8 (nonallergic: SI 1.1, CM allergic: SI 1.0) revealed lowest proliferation. The proliferation induced with M3 and M8 was as low as that obtained for the amino acid formulation M4 (nonallergic: SI 1.3, CM allergic: SI 1.1). It was interesting to note that milk formulas containing immunoreactive whey proteins (Fig. 1B: M1, M2, M5, M9, and M10) showed higher lymphocyte proliferation than the milk formula containing only caseins (Fig. 1B: M8). There were no statistical significant differences between the median SI observed for milk allergic and nonallergic individuals except for M6 with nonallergic individuals showing significantly higher SI (Fig. 3, P < 0.024).

In summary, the EH formulas M3 and M6 as well as the amino acid formulation M4 were the formulas which induced the least allergic/proinflammatory cytokine production in PBMCs from allergic as well as nonallergic subjects.

Discussion

Hydrolyzed CM formulas are used widely in the diet of CM-allergic children to prevent allergic reactions and for the prevention of allergic sensitization and allergy development in high-risk children. Here, we performed a blinded analysis of 10 different CM formulas regarding the presence of immunoreactive CM allergens/allergen fragments, IgE reactivity, allergic activity, ability to stimulate T-cell responses, and the secretion of a panel of different cytokines. In fact, hydrolyzed CM formulas have been tested already earlier regarding IgE reactivity, allergic activity, and in vivo allergenicity (19, 20), but the results of our study revealed some additional interesting aspects. It is assumed that extensively hydrolyzed CM formulas are less IgE-reactive and allergenic (10). Furthermore, it has been shown that EH formulas exhibit lower antigenicity and allergenicity when fed to infants than PH CM formulas (21). However, our analysis demonstrates that no significant differences between CM allergic and nonallergic subjects regarding the levels of IL-5 and IL-13 in the stimulated cultures (Fig. 4A,B). Second, M2, a PH formula, induced IL-5 and IL-13 as strongly as the nonhydrolyzed formula M1, whereas the other formulas were less active (Fig. 4A,B).

Similar findings were made for GM-CSF. Again, M1 and M2 induced high levels of GM-CSF, but in this case, also the other PH formula M5, and M10, the whole whey proteins, induced high levels of GM-CSF (Fig. 4C). Another difference as compared to IL-5 and IL-13 was that for all formulas but M5, GM-CSF levels were lower in PBMC cultures of allergic patients, although this was not statistically significant.

Next, we analyzed the proinflammatory cytokines IL-6 and TNF-α that gave similar profiles for the different formulas. The highest levels of IL-6 and TNF-α were found for formulas containing complete proteins (i.e. M1, M10), and the PH formulas M2 and M5 and, interestingly, also the EH formula M7 induced high levels of these cytokines (Fig. 4D,E). There was however one difference: IL-6 levels were higher in PBMC cultures of nonallergic subjects than in cultures of allergic patients, whereas no such differences were noted for TNF-α (Fig. 4D,E).

Regarding the Th1 cytokine IFN-γ, we found that IFN-γ levels were always higher in PBMC cultures from nonallergic subjects (Fig. 4F). Again, formulas containing complete proteins (M1, M10) but also the PH formulas M2 and M5 induced the highest levels of IFN-γ, followed by the EH formulas M6, M7, and the whole milk sample M9 (Fig. 4F).

For the IL-10, different profiles were observed: The highest levels of IL-10 were induced by the PH formula M5 and the complete whey proteins M10 (Fig. 4G). For M5 and M10, we did not find significant differences between allergic and nonallergic subjects. By contrast, IL-10 levels were always lower for each of the other tested formulas in allergic subjects.

In summary, the EH formulas M3 and M6 as well as the amino acid formulation M4 were the formulas which induced the least allergic/proinflammatory cytokine production in PBMCs from allergic as well as nonallergic subjects.
Milk formulas differ in allergenic activity

Hochwallner et al.

Allergy 72 (2017) 416–424 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.
certain EH formulas (e.g. M7, M8) similar as PH formulas (M2, M5) exhibited remaining IgE reactivity and/or allergic activity in basophil activation assays. Another interesting observation was that with the use of antibody probes specific for certain CM allergens, immune-reactive casein fragments were detected in formula M8 that was prepared from whey. It is thus quite likely that the residual IgE reactivity and allergic activity of this formula was due to the presence of remaining allergic casein-derived material. In fact, a similar finding was made recently by authors who studied time courses of whey hydrolysis and actually found that even after prolonged hydrolysis, patients showed IgE reactivity to caseins in the preparations (22). It is thus possible that hydrolyzed whey preparations may contain casein-derived peptides because they are less well hydrolyzed than the whey components.

The analysis of the capacity of the formulas to induce T-cell proliferation and cytokine secretion showed further differences among the formulas. The results of the T-cell proliferation experiments yielded similar results as observed earlier, in that PH formulas induced T-cell proliferation almost to the same extent as formulas containing complete allergen (23). However, only two of the four EH formulas (M3, M4) showed basically no remaining T-cell reactivity such as the amino acid formulation and thus proved to be non-T-cell stimulatory. Cow's milk formulas in which immune-reactive whey proteins were detected (i.e. M1, M2, M5, and M10) induced higher lymphocyte proliferation than the formula containing only caseins (i.e. M8). Interestingly, there were no relevant differences regarding the induction of T-cell proliferation between CM-allergic and nonallergic individuals. As the CM formulas are natural products, it cannot be excluded that carbohydrates or lipids in the formulas had an influence on the cellular responses but it is unlikely because proteins/peptides represent the major constituents of the CM formulas and the endotoxin levels in the preparations were very low.

The perhaps most interesting results came from the analysis of the induction of cytokines upon stimulation of PBMC with the CM formulas. In fact, we noted significant differences of the CM formulas to induce Th2, Th1, and proinflammatory cytokine responses. There were also significant differences regarding the production of proinflammatory cytokines such as IL-6 and the Th1 cytokine IFN-γ between allergic and nonallergic individuals. PBMC from nonallergic individuals secreted higher levels of IL-6 and IFN-γ than PBMCs from allergic individuals. It is possible that the proinflammatory cytokines are not exclusively derived from T cells, but this will reflect in vivo conditions where also other cell types are present similar as in PBMCs.

Most importantly, we found that three formulas (EH: M3 and M6; amino acid formulation: M4) did not induce any relevant levels of Th1, Th2, or proinflammatory cytokines, neither in PBMCs of allergic or nonallergic patients. This finding can most likely be explained by the lack of immunostimulatory peptides in these formulas which is consistent with the observation that they also did not stimulate T-cell proliferation. Interestingly, the formula M3 had been shown in the long-term German Infant Nutritional Intervention Study (GINI) to reduce the risk of developing AD, a T-cell-driven allergic skin manifestation (11). However, it must be noted that it is presently not clear if the induction of proinflammatory cytokines in PBMC samples is related to clinical symptoms.

In summary, our results demonstrate that there are striking differences among hydrolyzed CM formulas regarding IgE reactivity, allergic activity, and the ability to induce proinflammatory immune responses. It is quite possible that some of the discrepancies observed in clinical intervention trials and in the course of the clinical use of CM formulas for the prevention and treatment of CM allergy could be due to differences in the immunological and/or immunomodulatory properties of the various available preparations. It would thus seem to make sense to agree on common standardization protocols for the various CM formulas (24) similar as are used for example for standardization of diagnostic and therapeutic allergen extracts (25).

The finding that it is possible to identify CM formulas without allergic activity and no proinflammatory activity makes it tempting to speculate that such formulas might be useful not only for the prevention of CM allergy but maybe also for other inflammatory diseases. In this context, it has been suggested that inflammation in the gut and inflammatory processes leading to defects in the mucosal barrier may contribute to local and systemic autoimmunity (26–30).

Acknowledgments

This study was supported by research grants from the Austrian Science Fund (FWF), Projects P25921-B21, F4605, F4615 and by research grants from Biomay AG, Vienna, Austria and Mead Johnson Nutrition, Evansville, USA.

Author contributions

HH and RC performed experiments, analyzed data, wrote manuscript, and read manuscript; USCH, IS, MFT, SS, NB, and RR performed experiments, analyzed data, and read manuscript; JT, FH, MO, NGS, SQ, ZS, UH, ETV, and SSP analyzed data and read manuscript; and RV designed and supervised experiments, analyzed data, wrote manuscript, and read manuscript.
Milk formulas differ in allergenic activity

Hochwalner et al.

Conflicts of interest
Rudolf Valenta and Heidrun Hochwalner have received research grants from the Austrian Science Fund (FWF). Rudolf Valenta has received research grants from Biomay AG, Vienna, Austria, and Thermofisher, Uppsala, Sweden, and serves as a consultant for these companies.

References
1. Burks AW, Tang M, Sicherer S, Muraro A, Eigenmann PA, Ebisawa M et al. ICON: food allergy. J Allergy Clin Immunol 2012;129:906–920.
2. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 2014;133:291–307.
3. Burney PG, Potts J, Kummeling I, Mills EN, Clausen M, Dubaikhan R et al. The prevalence and distribution of food sensitization in European adults. Allergy 2014;69:365–371.
4. Schmitz R, Ellert U, Kaeckesch M, Dahm S, Thamm M. Patterns of sensitization to inhalant and food allergens – findings from the German Health Interview and Examination Survey for Children and Adolescents. Int Arch Allergy Immunol 2013;162:263–270.
5. Hochwalner H, Schulmeister U, Swoboda I, Spitzauer S, Valenta R. Cow’s milk allergy: from allergens to new forms of diagnosis, therapy and prevention. Methods 2014;66:22–33.
6. Host A, Hallen S. Hypoallergenic formulas – when, to whom and how long: after more than 15 years we know the right indication!. Allergy 2004;59(Suppl 78):45–52.
7. Hays T, Wood RA. A systematic review of the role of hydrolyzed infant formulas in allergy prevention. Arch Pediatr Adolesc Med 2005;159:810–816.
8. Koletzko S, Niggemann B, Arato A, Dias JA, Heuschkel R, Husby S et al. Diagnostic approach and management of cow’s milk protein allergy in infants and children: ESPGHAN Gi Committee practical guidelines. J Pediatr Gastroenterol Nutr 2012;55:221–229.
9. Longo G, Berti I, Burks AW, Kraus B, Barb E. IgE-mediated food allergy in children. Lancet 2013;382:1656–1664.
10. Vandenplas Y, Bhatia J, Shamir R, Agostoni C, Tuck D, Staiano A et al. Hydrolyzed formulas for allergy prevention. J Pediatr Gastroenterol Nutr 2014;58:549–552.
11. von Berg A, Koletzko S, Grubl A, Filipiak-Pittroff B, Wichmann HE, Bauer CP et al. The effect of hydrolyzed cow’s milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 2003;111:533–540.
12. von Berg A, Filipiak-Pittroff B, Kramer U, Hoffmann L, Link E, Beckmann C et al. Allergies in high-risk schoolchildren after early intervention with cow’s milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. J Allergy Clin Immunol 2013;131:1565–1573.
13. von Berg A, Filipiak-Pittroff B, Kramer U, Link E, Bollrath C, Brockow I et al. Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI). J Allergy Clin Immunol 2008;121:1442–1447.
14. von Berg A, Koletzko S, Filipiak-Pittroff B, Laubereau B, Grubl A, Wichmann HE et al. Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma: three-year results of the German Infant Nutritional Intervention Study. J Allergy Clin Immunol 2007;119:718–725.
15. Schulmeister U, Hochwalner H, Swoboda I, Focke-Tejkl M, Geller B, Nystrad M et al. Cloning, expression, and mapping of allergenic determinants of alphaS1-casein, a major cow’s milk allergen. J Immunol 2009;182:7019–7029.
16. Jacobs S. Determination of nitrogen in proteins by means of iodanidetane hydrate. Nature 1959;183:262.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
18. Kaul S, Luttkopf D, Kastner B, Vogel L, Holtz G, Vieths S et al. Mediator release assays based on human or murine immunoglobulin E in allergen standardization. Clin Exp Allergy 2007;37:141–150.
19. Niggemann B, Binder C, Kletke U, Wahn U. In vivo and in vitro studies on the residual allergenicity of partially hydrolysed infant formulae. Acta Paediatr 1999;88:394–398.
20. Niggemann B, Nies H, Renz H, Herz U, Wahn U. Sensitizing capacity and residual allergenicity of hydrolyzed cow’s milk formulae: results from a murine model. Int Arch Allergy Immunol 2001;125:316–321.
21. Oldaeus G, Bjorksten B, Jenmalm MC, Kjellman NI. Cow’s milk IgE and IgG antibody responses to cow’s milk formulas. Allergy 1999;54:352–357.
22. Meulenbroek LA, Oliveira S, den Hartog Jager CF, Klemans RJ, Lebens AF, van Baalen T et al. The degree of whey hydrolysis does not uniformly affect in vitro basophil and T cell responses of cow’s milk allergic patients. Clin Exp Allergy 2014;44:529–539.
23. Szepfalusi Z, Nentwich I, Jost E, Gerstmayr M, Ebner C, Frischer T et al. Cord blood mononuclear cells and milk-specific T-cell clones are tools to evaluate the residual immunogenicity of hydrolyzed milk formulas. J Allergy Clin Immunol 2006;118:514–520.
24. Koletzko B, Shamir R. Standards for infant formula milk. BMJ 2006;332:621–622.
25. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310–326.
26. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011;12:5–9.
27. Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol 2014;26:101–107.
28. Sonier B, Patrick C, Ajjikuttira P, Scott FW. Intestinal immune regulation as a potential diet-modifiable feature of gut inflammation and autoimmunity. Int Rev Immunol 2009;28:414–445.
29. Vaarala O. Leaking gut in type 1 diabetes. Curr Opin Gastroenterol 2008;24:701–706.
30. Silva MA. Intestinal dendritic cells and epithelial barrier dysfunction in Crohn’s disease. Inflamm Bowel Dis 2009;15:436–453.

Allergy 72 (2017) 416–424 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.